Biogen, Sobi present new data from Phase III study of Eloctate for hemophilia A
A clotting factor, Eloctate is under development using Biogen Idec’s novel and proprietary monomeric Fc fusion technology. Announced at the XXIV International Society on Thrombosis and Haemostasis (ISTH)
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.